Media Articles Related to Paragard T380a (Copper Intrauterine)
'15 million unwanted pregnancies' created by low contraception in 35 poorer countries
Source: Abortion News From Medical News Today [2015.02.05]
Some 90% of the 16.7 million unwanted pregnancies across a third of the world's population every year are due to a failure to use modern contraception, study suggests.
Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.
Contraceptive study seeks to reduce unintended pregnancies, Australia
Source: Medical Students / Training News From Medical News Today [2015.01.16]
A major four-year trial will offer GPs across Victoria specialised training on contraception to reduce the number of unintended pregnancies by increasing uptake of Long Acting Reversible...
New research shows a statistical significant association between increased LARC usage and reduction in teenage pregnancy and abortion rates in England
Source: Abortion News From Medical News Today [2014.11.27]
New findings, published in the International Journal of Women's Health, show increased long-acting reversible contraception (LARC) usage in England was significantly associated with decreased...
Free birth control reduces teen pregnancies and abortions
Source: Abortion News From Medical News Today [2014.10.03]
Teens who received free contraception and were educated about the pros and cons of various birth control methods were dramatically less likely to get pregnant, give birth or get an abortion compared...
Published Studies Related to Paragard T380a (Copper Intrauterine)
Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial. [2011.09]
OBJECTIVE: To compare intrauterine device (IUD) use at 6 months in women randomized to receive an intrauterine copper contraceptive 1 week compared with 1 month after medical abortion... CONCLUSION: Immediate insertion increased uptake of the IUD without increasing expulsions or bleeding. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, www.clinialtrials.gov, . LEVEL OF EVIDENCE: I.
Immediate vs. delayed post-abortal copper T 380A IUD insertion in cases over 12 weeks of gestation. [2011.06]
BACKGROUND: The intrauterine device (IUD) is a safe, effective, well-tolerated form of contraception. Immediate placement after second-trimester abortion could increase high-tier contraception use in women who are at high risk for unintended pregnancy... CONCLUSION: Placing the IUD immediately after the procedure significantly increases the likelihood of use of effective contraception following a second-trimester procedure. Women who have an IUD placed immediately after their procedure may also be less likely to have a subsequent unplanned pregnancy. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Copper containing intra-uterine devices versus depot progestogens for contraception. [2010.06.16]
CONCLUSIONS: In the populations studied, the IUD was more effective than hormonal contraception with respect to pregnancy prevention. High quality research is urgently needed to compare the effects, if any, of these two commonly used contraception methods on HIV acquisition/seroconversion and HIV/AIDS disease progression.
Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A. [2010.02]
BACKGROUND: Intrauterine contraception can provide adolescents with effective, long-term contraception as well as with other health benefits. In adult populations, intrauterine contraception rates highly in patient satisfaction and safety. It is rarely prescribed to adolescents because of limited data... CONCLUSIONS: This study shows that at 6 months, though not statistically significant, adolescent continuation rates trended towards being greater with the Levonorgestrel Intrauterine System compared to the Copper T 380A. These pilot data will be helpful in the design of a larger trial of intrauterine contraception use among adolescents.
The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. [2009.08]
BACKGROUND: Clinical performance of the frameless copper IUD (GyneFix), designed to reduce side effects related to the frame of conventional IUDs, and TCu380A was compared... CONCLUSIONS: The frameless IUD had more insertion failures, expulsions and pregnancies in the first year than TCu380A, but fewer pregnancies from the second through the eighth year, and by 8 years had fewer ectopic pregnancies and removals for pain.
Clinical Trials Related to Paragard T380a (Copper Intrauterine)
Quick Start Insertion of Mirena and ParaGard [Recruiting]
Intrauterine devices (IUDs) are an effective form of contraception, but only about 3. 4% of
women in the US report using them. Women must often wait for their menses to start, or for
results of screening for sexually transmitted infections (STIs), before their doctors will
place IUDs for them. This is not the case with other birth control methods. Researchers know
that it is safe to start oral contraceptive pills, transdermal patches or vaginal rings on
the same day of a doctor's visit. In the investigators clinical practice, the investigators
often place IUDs on the same day of a woman's visit, but outcomes have not been formally
Currently, there are two kinds of IUDs available in the United States: the ParaGard T380A
and the Mirena levonorgestrel intrauterine system (LNG-IUS). The investigators want to know
if women who have IUDs placed at any time during their menstrual cycle have different
experiences regarding the following, compared to those who have IUDS placed during the first
7 days of their cycle: bleeding or cramping patterns, active pelvic infections, becoming
pregnant more often during that first cycle (window pregnancy).
Women who come to their provider seeking an IUD for birth control will be asked to
participate in this study. The investigators will ask them to keep track of their bleeding
and cramping for three subsequent months to see if patterns differ according to the day in
their menstrual cycle that the device was inserted. They will be randomly assigned either
to record this information on paper, or to send in the information by responding to daily
The investigators want to know if women who have an IUD placed at any time during the
menstrual cycle have different outcomes compared to those who have IUDs placed during the
first 7 days of their cycle. If the investigators have this information, the investigators
can make recommendations to physicians, help counsel patients, and potentially expand access
Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes [Recruiting]
The study is being done in order to gain information on the most suitable types of birth
control in women who recently had gestational diabetes, or diabetes diagnosed during
pregnancy. The intrauterine device (IUD) is a highly effective form of birth control. It is
inserted into the uterus and prevents pregnancy for either 5 or 10 years, depending on the
type of IUD (hormone-releasing or copper). The hormone-releasing IUD works for 5 years and
releases a hormone called a progestin into the uterus. The copper IUD contains no hormones
and works for 10 years. The IUD is an excellent form of birth control postpartum, but it is
unknown if the hormone-releasing IUD will affect blood sugars and increase a woman's risk of
becoming diabetic when she's not pregnant. The hypothesis is that the hormone-containing IUD
will NOT increase blood sugars, so women who use the hormone-containing IUD will have
similar blood sugars to those who use the copper IUD or have had their tubes tied (no
Early Postpartum Intrauterine Device (IUD) Placement [Recruiting]
Women who have just given birth are at high risk for rapid repeat pregnancy, which can lead
to negative consequences during the subsequent pregnancy. Providers have traditionally
delayed starting birth control, especially placement of intrauterine devices (IUDs),
post-delivery for a number of reasons. The first postpartum visit after a woman has given
birth is typically scheduled for 6 weeks after her delivery, during which she is typically
provided with her chosen method of birth control. This study will evaluate two different IUD
placement times: 3 weeks and 6 weeks after delivery. This will allow the researchers to
determine if placement time affects a woman's follow-through obtaining the IUD and keeping
it inserted in place. The researchers will also look at bleeding patterns and
patient/provider satisfaction with the IUD placement
Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement [Recruiting]
Intrauterine device (IUD) placement can be painful for patients during and after the
procedure. Fear of pain from IUD insertion can be a barrier to obtaining this highly
effective long acting reversible contraception. Currently there are no proven effective
methods for reduction of pain during and after placement of modern IUDs (Mirena IUD and
Paragard IUD). Ketorolac has not been studied in regards to decreasing pain during and after
IUD insertion although it is used by some providers for this purpose. It is a strong NSAID
that is indicated for the treatment of moderate acute pain. In the intramuscular form it has
an analgesia onset of action at 30min, thus may be a plausible option for pain management in
the office setting compared to oral NSAIDs, which have a longer time to onset of analgesia
and have not been proven to be effective in reducing pain associated with IUD placement. The
primary aim of this study is to determine whether ketorolac (Toradol) decreases pain
associated with intrauterine device placement compared to placebo. We hypothesize that
administration of ketorolac 30mg intramuscularly at least 30 minutes prior to IUD insertion
will decrease pain scores by at least 20mm on a visual analog scale at various time points
during IUD insertion when compared to placebo of normal saline injection.
Immediate Postplacental IUD [Recruiting]
The study will be a randomized clinical trial. Women with less than 10 prenatal visits
and/or 2 or more no show visits who desire an Intrauterine Device (IUD) will be considered
for enrollment. If consented and meet inclusion criteria, they will be randomized after
delivery to receive an IUD immediately postplacental or at their routine postpartum visit.
Women who plan to deliver a live birth singleton via vaginal or cesarean delivery at Oregon
Health and Science University (OHSU) hospital will be considered for inclusion in the study.
Women who desire an IUD for postpartum contraception will be approached for study
participation. The postpartum contraception plan is routinely documented during their
prenatal course. It is also addressed by the obstetrical team upon admission to Labor &
Delivery at OHSU. The obstetrical team will identify subjects who present in labor who meet
the criteria of poor prenatal clinic attendance and express interest in intrauterine
contraception. Immediately after vaginal or cesarean delivery, consented subjects will be
randomized to immediate postplacental IUD placement or IUD placement at their routine
postpartum visit. Women randomized to the immediate postplacental IUD group will receive
their IUD within 60 minutes of placental delivery. Prior to discharge from the hospital
women who received a postplacental IUD will be assisted in scheduling a routine postpartum
visit with their primary provider. Subjects who are randomized for IUD insertion at their
postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with
their usual obstetrical care provider. All subjects in the delayed group will be provided
with contact information for the Women's Health Research Unit (WHRU) at OHSU. If a subject
cannot obtain an IUD at her usual place of care, the device will be placed at no cost
through the WHRU.
At 3 months after delivery, all subjects will be contacted by phone, text, or email to
complete a questionnaire to determine whether they have had a known expulsion, pregnancy, or
elective IUD removal. The questionnaire will include questions regarding ease of placement
and overall satisfaction with the timing of placement. Subjects will be compensated for
their participation in the study after the 3 month contact.